Overview
The purpose of this study is to investigate the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOAC) in atrial fibrillation patients with intermediate stroke risk (CHA2DS2-VASc score 1 for male, 2 for female).
- Major safety results include major bleeding and clinically relevant non-major bleeding.
- Major efficacy results include strokes, systemic embolism and cardiovascular mortality.
- Other results include myocardial infarction, pulmonary embolism, transient ischemic attack, hospitalization, drug compliance, quality of life questionnaire (AFEQT), cognitive function (KDSQ), aging questionnaire(K-Frail) and hand grip strength.
Eligibility
Inclusion Criteria:
- Age: 19\~80 years old
- CHA2DS2-VASc score 1 for male or 2 for female among nonvalvular atrial fibrillation patients
- Patients who agree to register for this study
- Patients who can be observed for the progress after treatment
Exclusion Criteria:
- Severe liver or kidney dysfunction
- Thyroid dysfunction
- Pregnant or breastfeeding women
- Malignant tumors that have not been completely cured
- Severe structural heart disease
- Predicted survival is less than 12 months
- Patients who do not understand the content of the study or disagree with it
